bioMérieux is first and foremost a human and scientific adventure that began more than 55 years ago. Our expertise and our commitment to expand the frontiers of knowledge in biology are rooted in an entrepreneurial story that has been ongoing for more than a century. In 1897, Marcel Mérieux, who had studied under Louis Pasteur, founded his laboratory in Lyon where he developed the first anti-tetanus sera. From the very beginning, the Institut Mérieux laid the groundwork for a bio-industrial organization that would impact both vaccinology and later on the diagnosis of infectious diseases on a global scale. bioMérieux, headquartered in Marcy l'Étoile, France, was created in 1963 by Alain Mérieux. Since 2014, Alexandre Mérieux, the great-grandson of Marcel, has been at the helm of this family owned company as Chief Executive Officer. In December 2017, he was appointed Chairman and CEO by the Board of Directors. The Company specializes in providing in vitro diagnostics solutions (systems, reagents, software and services) whose primary purpose is to identify certain pathogens. Our products are mainly used in the clinical field for diagnosing infectious diseases, and in the industrial field for the detection of microorganisms in agri-food, pharmaceutical and cosmetic products. Our solutions contribute to improving patient health and ensuring consumer safety. bioMérieux today employs nearly 13,000 people. We are present in 44 countries and serve more than 160 countries with the support of a large network of distributors.